Submitted to: Patent Application
Publication Type: Patent Application
Publication Acceptance Date: 2/18/2003
Publication Date: 2/18/2003
Citation: JENKINS, M.C., TROUT, J.M., FAYER, R. A 41 KDA CRYPTOSPORIDIUM PARVUM OOCYST WALL PROTEIN: BACKGROUND OF THE INVENTION. PATENT APPLICATION. 2003.
Interpretive Summary: Cryptosporidiosis is an intestinal disease of the young and immunocompromised causing a variety of symptoms including diarrhea and poor growth. At present, there are no drugs available to prevent or treat the infection. Thus, public health officials and water utilities have concentrated on developing methods for detecting and removing Cryptosporidium parvum from water. While sensitive and specific detection methods are useful, the ideal diagnostic assay would differentiate live from dead oocysts. If C. parvum oocysts are detected in a water sample, but the oocysts are not viable, then the immediacy of treating the water and notifying the public is lessened. This patent makes claims to a technique that measures the level of messenger RNA for the CP41 gene sequence and correlates these levels with the viability of the oocysts. The goal of this research is to develop a practical, effective, and timely method for identifying C. parvum oocysts in water and further determining whether the parasites are viable.
Technical Abstract: Cryptosporidium parvum is a protozoan parasite that has been implicated in numerous outbreaks of diarrheal disease in the human population. This invention related to an isolated 41 kDa protein, CP41, specific for C. parvum; recombinant CP41 (rCP41) proteins: a recombinant 36 kDa protein and a recombinant 28 kDa protein, both of which are specific for C. parvum; and the nucleic acid sequences which encode these proteins. The DNA which encodes CP41 and rCP41 can be used to specifically identify C. parvum oocysts through RT-PCR. The isolated and recombinant proteins can be used as reagents to detect antibodies in the serum of infected individuals, to make monoclonal antibodies that are specific for the native 41 kDa protein which specifically identifies C. parvum and thus distinguishes C. parvum from other Cryptosporidium species, to generate hyperimmune serum or colostrum for use in enhancing the anti-cryptosporidium response of young or immunocompromised individuals, and in vaccine development, to protect individuals from Cryptosporidium infection.